Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Earnings Results, Beats Expectations By $0.25 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) issued its quarterly earnings data on Monday. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25, Briefing.com reports. Supernus Pharmaceuticals had a return on equity of 7.94% and a net margin of 9.16%. The business had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same period in the previous year, the firm posted ($0.29) earnings per share. The business’s revenue was up 14.2% on a year-over-year basis. Supernus Pharmaceuticals updated its FY 2024 guidance to EPS.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock traded up $2.43 during mid-day trading on Wednesday, hitting $37.17. 106,420 shares of the stock traded hands, compared to its average volume of 447,691. Supernus Pharmaceuticals has a twelve month low of $23.05 and a twelve month high of $39.37. The company’s 50-day simple moving average is $33.02 and its 200-day simple moving average is $30.54. The firm has a market cap of $2.05 billion, a price-to-earnings ratio of 32.47 and a beta of 0.86.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Cowen reissued a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Piper Sandler restated a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.